Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
2.570
-0.140 (-5.17%)
Jun 27, 2025, 10:37 AM - Market open
Jaguar Health Stock Forecast
JAGX's stock price has decreased by -97.32% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Jaguar Health stock has a target of 60, which predicts a 2234.63% increase from the current stock price of 2.57.
Price Target: $60 (+2234.63%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 19, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Jaguar Health is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|
| Strong Buy | 0 | 1 | 1 |
| Buy | 1 | 0 | 0 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| First Berlin | First Berlin | Strong Buy Initiates $60 | Strong Buy | Initiates | $60 | +2,234.63% | May 19, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $1,687,500 | Buy | Initiates | $1,687,500 | +65,661,378.60% | Jul 7, 2021 |
Financial Forecast
Revenue This Year
14.31M
from 11.69M
Increased by 22.41%
Revenue Next Year
18.60M
from 14.31M
Increased by 30.00%
EPS This Year
-24.29
from -130.69
EPS Next Year
-5.79
from -24.29
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 |
|---|---|---|
| High | 14.7M | 19.1M |
| Avg | 14.3M | 18.6M |
| Low | 13.7M | 17.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 |
|---|---|---|
| High | 26.0% | 33.8% |
| Avg | 22.4% | 30.0% |
| Low | 17.6% | 24.9% |
EPS Forecast
| EPS | 2025 | 2026 |
|---|---|---|
| High | -25.00 | -5.96 |
| Avg | -24.29 | -5.79 |
| Low | -23.33 | -5.57 |
EPS Growth
| EPS Growth | 2025 | 2026 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.